Literature DB >> 9564630

(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B.

J Sterling1, A Veinberg, D Lerner, W Goldenberg, R Levy, M Youdim, J Finberg.   

Abstract

(+)-N-Propargyl-1-aminoindan (rasagiline) and a series of derivatives have been synthesized and screened for monoamine oxidase inhibitory activity. Rasagiline and several analogues were found be highly selective and potent inhibitors of the B form of the enzyme in contrast to the levorotatory enantiomer which was not active. The results indicate that rasagiline has potential for the treatment of Parkinson's Disease. This compound is currently under development for that indication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564630     DOI: 10.1007/978-3-7091-6499-0_30

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  6 in total

1.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

3.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

Review 4.  The role of rasagiline in the treatment of Parkinson's disease.

Authors:  Julie Leegwater-Kim; Elena Bortan
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

5.  Successful use of rasagiline in combination with two antidepressants: a case report.

Authors:  Narpinder Kaur; Rohit Madan; Ashish Sharma
Journal:  Innov Clin Neurosci       Date:  2012-11

6.  Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.

Authors:  Orly Weinreb; Tamar Amit; Yotam Sagi; Noam Drigues; Moussa B H Youdim
Journal:  J Neural Transm (Vienna)       Date:  2009-04-25       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.